Deciphering the regulatory logic of the ubiquitin system
This project aims to elucidate the substrate recognition mechanisms of E3 ubiquitin ligases using functional genetic approaches to enhance understanding of the ubiquitin-proteasome system for therapeutic applications.
Projectdetails
Introduction
As the primary route through which eukaryotic cells achieve selective protein degradation, the ubiquitin-proteasome system (UPS) plays a key role in virtually all critical cellular processes. A major unresolved question concerns how the ubiquitin system attains such high selectivity towards its myriad of substrates.
Specificity Determinants
The main specificity determinants are the E3 ubiquitin ligases, which recognise cognate degron motifs found in substrate proteins. However, for the majority of the ~600 E3 ligases encoded in the human genome, we still have little or no knowledge as to their substrates, and our understanding of degron motifs remains limited.
Knowledge Gap
This knowledge gap prevents us from appreciating how key cellular processes are regulated and impedes the development of small molecules capable of either inhibiting or hijacking E3 ligases for therapeutic benefit.
Research Approach
To complement the biochemical and proteomic techniques that have served as the primary route to discovery in the field, we seek to exploit functional genetic approaches to understand how E3 ligases recognise their substrates.
Specific Goals
Leveraging an expression screening platform that enables proteome-wide stability profiling, our specific goals are to:
- Identify physiological substrates regulated via degrons lying at their extreme C-termini.
- Define novel mechanisms through which conditional protein degradation is achieved via phospho-degrons.
- Characterise the spectrum of degradative pathways responsible for the instability of hundreds of the most short-lived cellular proteins.
Methodology
For each goal, we will first provide global insight by systematically interrogating the proteome for relevant substrates. For the most interesting candidates, we will then seek detailed mechanistic understanding to illuminate new biology.
Conclusion
Successful completion of this work will transform our understanding of how specificity is achieved within the UPS and greatly facilitate its future therapeutic manipulation.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.528.843 |
Totale projectbegroting | € 1.528.843 |
Tijdlijn
Startdatum | 1-3-2025 |
Einddatum | 28-2-2030 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Ubiquitin-Proteasome System crosstalk with MetabolismThis project aims to elucidate the regulatory crosstalk between ubiquitination and cellular metabolites using advanced biophysical techniques to enhance understanding of metabolic homeostasis. | ERC Advanced... | € 2.089.688 | 2023 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC Starting... | € 1.499.625 | 2022 | Details |
(Re-)Writing the Ubiquitin Code – Manipulating Polyubiquitin Chain Linkage to Investigate Ubiquitin Signalling in Genome Maintenance and BeyondThis project aims to develop innovative tools for studying polyubiquitylation's role in genome maintenance and its implications for cancer and aging, enhancing our understanding of cellular signaling pathways. | ERC Advanced... | € 2.499.799 | 2025 | Details |
Cellular Strategies of Protein Quality Control-DegradationThis project aims to uncover the molecular mechanisms of stress-induced protein quality control and E3 ubiquitin ligases to combat neurodegeneration from chronic protein damage. | ERC Advanced... | € 2.500.000 | 2025 | Details |
ADPribosylation and Ubiquitination; post-translational interplayThis project aims to investigate the interplay between ubiquitination and ADPribosylation in cellular processes to develop novel therapeutic strategies for diseases like infections and cancer. | ERC Consolid... | € 1.999.625 | 2024 | Details |
Ubiquitin-Proteasome System crosstalk with Metabolism
This project aims to elucidate the regulatory crosstalk between ubiquitination and cellular metabolites using advanced biophysical techniques to enhance understanding of metabolic homeostasis.
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.
(Re-)Writing the Ubiquitin Code – Manipulating Polyubiquitin Chain Linkage to Investigate Ubiquitin Signalling in Genome Maintenance and Beyond
This project aims to develop innovative tools for studying polyubiquitylation's role in genome maintenance and its implications for cancer and aging, enhancing our understanding of cellular signaling pathways.
Cellular Strategies of Protein Quality Control-Degradation
This project aims to uncover the molecular mechanisms of stress-induced protein quality control and E3 ubiquitin ligases to combat neurodegeneration from chronic protein damage.
ADPribosylation and Ubiquitination; post-translational interplay
This project aims to investigate the interplay between ubiquitination and ADPribosylation in cellular processes to develop novel therapeutic strategies for diseases like infections and cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Universal GPCR Activity Sensor for Next Generation Drug DiscoveryThis project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures. | EIC Pathfinder | € 2.965.384 | 2023 | Details |
Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.